Valuation: Positron Corporation

Market Cap 56.17M 49.23M 45.51M 41.85M 78.97M 5.42B 80.23M 544M 213M 2.65B 211M 206M 9.13B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 55.03M 48.23M 44.58M 41M 77.37M 5.31B 78.61M 533M 209M 2.6B 207M 202M 8.95B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day+3.64%
1 week+3.64%
Current month-9.04%
1 month-6.04%
3 months-10.00%
6 months+4.91%
Current year+2.40%
1 week 1.43
Extreme 1.43
1.74
1 month 1.43
Extreme 1.43
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.64%+3.64%+17.32%-1.72% 54.2M
+6.91%+8.87%-7.74%-12.60% 13.35B
-2.62%-10.96%+37.34%-12.44% 3.86B
0.00%-0.68%+71.16%+108.49% 1.24B
+1.96%+1.10%-33.97%-59.49% 1.18B
+1.04%-0.28%-39.88%-45.92% 1.09B
+0.40%+7.25%-42.58% - 940M
-4.05%-16.17%+54.47%+83.21% 490M
+0.60%+8.52%+48.35% - 335M
+1.09%+4.24%-56.19%+242.71% 265M
Average +0.90%-0.53%+4.83%+37.78% 2.28B
Weighted average by Cap. +3.71%+1.94%+1.50%-4.52%

Financials

2024 2025
Net sales 588K 515K 476K 438K 826K 56.65M 839K 5.69M 2.23M 27.72M 2.21M 2.16M 95.5M 461K 404K 374K 344K 649K 44.5M 659K 4.47M 1.75M 21.77M 1.73M 1.69M 75.01M
Net income -2.38M -2.09M -1.93M -1.77M -3.34M -229M -3.4M -23.05M -9.03M -112M -8.93M -8.74M -387M -10.6M -9.29M -8.59M -7.9M -14.91M -1.02B -15.15M -103M -40.27M -500M -39.82M -38.95M -1.72B
Net Debt 1.42M 1.25M 1.15M 1.06M 2M 137M 2.03M 13.8M 5.41M 67.21M 5.35M 5.23M 232M -1.14M -996K -921K -847K -1.6M -110M -1.62M -11.01M -4.31M -53.61M -4.27M -4.17M -185M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
20/07/26 USD 1.710 +3.64% 27,900
17/07/26 USD 1.650 +0.41% 27,059
16/07/26 USD 1.643 -3.34% 2,125
15/07/26 USD 1.700 +9.68% 19,501
14/07/26 USD 1.550 -6.06% 30,756
  1. Stock Market
  2. Stocks
  3. POSC Stock